PET/CT Basics

Medical imaging studies can be divided into structural vs. functional modalities, with PET imaging being a common functional modality used in daily practice. PET imaging involves introducing positron-emitting radiotracers into the body and acquiring three-dimensional image maps of their distribution, which can help diagnose various conditions by highlighting abnormal metabolic processes. FDG-PET/CT imaging is particularly useful in oncology for detecting abnormal glucose uptake associated with cancer, although its effectiveness can vary across different cancer types and it may produce false positives or negatives due to various physiological and pathological factors.

Chapters:
00:00 - Introduction
00:59 - The Science behind PET Imaging
06:22 - The Clinical Process
12:43 - Applications in Neurology
13:30 - Applications in Cardiology
14:23 - Applications in Oncology
15:07 - FDG-PET & Brain Cancer
15:49 - FDG-PET & Bladder Cancer
16:17 - FDG-PET & Breast Cancer
16:50 - FDG-PET & Colorectal Cancer
17:48 - FDG-PET & Esophageal Cancer
18:56 - FDG-PET & Head/Neck Cancer
19:31 - FDG-PET & Kidney Cancer
20:05 - FDG-PET & Lung Cancer
20:33 - FDG-PET & Lymphoma
21:49 - FDG-PET & Melanoma
22:18 - FDG-PET & Ovarian Cancer
22:57 - FDG-PET & Cervical Cancer
23:28 - FDG-PET & Prostate/Testicular Cancer
23:46 - Non-FDG Radiotracers in Oncology
26:18 - False Positives in FDG-PET Imaging
27:02 - False Negatives in FDG-PET Imaging
27:44 - Normal Tissues with High FDG Uptake